255 related articles for article (PubMed ID: 24621498)
1. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
Willerslev-Olsen A; Litvinov IV; Fredholm SM; Petersen DL; Sibbesen NA; Gniadecki R; Zhang Q; Bonefeld CM; Wasik MA; Geisler C; Zhou Y; Woetmann A; Sasseville D; Krejsgaard T; Odum N
Cell Cycle; 2014; 13(8):1306-12. PubMed ID: 24621498
[TBL] [Abstract][Full Text] [Related]
2. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.
Krejsgaard T; Litvinov IV; Wang Y; Xia L; Willerslev-Olsen A; Koralov SB; Kopp KL; Bonefeld CM; Wasik MA; Geisler C; Woetmann A; Zhou Y; Sasseville D; Odum N
Blood; 2013 Aug; 122(6):943-50. PubMed ID: 23801634
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
4. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
5. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.
Nielsen M; Kaltoft K; Nordahl M; Röpke C; Geisler C; Mustelin T; Dobson P; Svejgaard A; Odum N
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6764-9. PubMed ID: 9192639
[TBL] [Abstract][Full Text] [Related]
7. Systemic chemotherapy promotes HIF-1α-mediated glycolysis and IL-17F pathways in cutaneous T-cell lymphoma.
Wang B; Li K; Wang H; Shen X; Zheng J
Exp Dermatol; 2020 Oct; 29(10):987-992. PubMed ID: 32573814
[TBL] [Abstract][Full Text] [Related]
8. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma.
Sakamoto M; Miyagaki T; Kamijo H; Oka T; Boki H; Takahashi-Shishido N; Suga H; Sugaya M; Sato S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360654
[TBL] [Abstract][Full Text] [Related]
9. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
11. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression.
Asadullah K; Haeussler-Quade A; Gellrich S; Hanneken S; Hansen-Hagge TE; Döcke WD; Volk HD; Sterry W
Exp Dermatol; 2000 Aug; 9(4):248-51. PubMed ID: 10949545
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS).
Jothishankar B; Venkataraman G; Goldberg RC; Abdulla F
Ann Diagn Pathol; 2019 Dec; 43():151404. PubMed ID: 31629155
[No Abstract] [Full Text] [Related]
13. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
[TBL] [Abstract][Full Text] [Related]
14. Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides.
Papathemeli D; Patsatsi A; Papanastassiou D; Koletsa T; Papathemelis T; Avgeros C; Pikou O; Lazaridou E; Georgiou E
Acta Derm Venereol; 2020 Nov; 100(18):adv00326. PubMed ID: 33170303
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
17. The role of IL-32 in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Kawaguchi M; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2014 May; 134(5):1428-1435. PubMed ID: 24226419
[TBL] [Abstract][Full Text] [Related]
18. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications.
Alcántara-Hernández M; Torres-Zárate C; Pérez-Montesinos G; Jurado-Santacruz F; Domínguez-Gómez MA; Peniche-Castellanos A; Ferat-Osorio E; Neri N; Nambo MJ; Alvarado-Cabrero I; Moreno-Lafont M; Huerta-Yepez S; Bonifaz LC
Int J Cancer; 2014 May; 134(9):2136-45. PubMed ID: 24127318
[TBL] [Abstract][Full Text] [Related]
20. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
